EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

CREST ‐ UK : Real‐world effectiveness, safety and outpatient delivery of CPX ‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UK

Priyanka Mehta iD, Victoria Campbell, Jamie Maddox iD, Yngvar Floisand, Anita J M Kalakonda, Jenny O'Nions iD, Thomas Coats iD, Sateesh Nagumantry, Katherine Hodgson, Richard Whitmill, Ian Amott, Gillian Flynn und 10 weitere

British Journal of Haematology · 2024-10 · 205 (4) · 1326-1336

DOI: 10.1111/bjh.19622 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 08.07.2024. Verfasst von Priyanka Mehta und 21 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Cytarabine, Myelodysplastic Syndromes. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Favourable outcomes with CPX‐351 versus conventional 7 + 3 were demonstrated in the pivotal phase III trial in adults aged 60–75 years with newly diagnosed, highrisk/secondary acute myeloid leukaemia (AML). As a complement to the clinical trial and to address important data gaps, the C PX‐351 R eal‐World E ffectiveness and S afe T y (CREST‐UK; NCT05169307) study evaluated the use of CPX‐351 in routine clinical practice in the UK, in 147 patients with newly diagnosed therapy‐related AML or AML with myelodysplasia‐related changes. Best response of complete remission or complete remission with incomplete platelet or neutrophil recovery was achieved by 53% of evaluable patients. Kaplan–Meier median overall survival (OS) was 12.8 months (95% confidence interval 9.2–15.3). Fifty (34%) patients proceeded to haematopoietic cell transplantation (HCT); median OS landmarked from the HCT date was not reached. There were no new safety concerns with CPX‐351 identified in CREST‐UK. Patients treated with CPX‐351 in the outpatient setting spent an average of 24.4, 16.7, 28.2, and 27.7 fewer days on the ward compared with inpatients during first induction, second induction, first consolidation, and second consolidation, respectively. The results from CREST‐UK provide valuable insights into the effectiveness, safety, and outpatient delivery of CPX‐351 in routine clinical practice in the UK.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteCytarabineMyelodysplastic SyndromesHumansAgedMiddle AgedMaleFemaleUnited KingdomDaunorubicinAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeAdultHematopoietic Stem Cell TransplantationNeoplasms, Second Primary

Stichwörter der Autor:innen

CPX‐351acute myeloid leukaemiachemotherapyclinical observationsreal‐world

Substanzen

CytarabineCPX-351Daunorubicin

Autor:innen und Institutionen

  • University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
  • Western General Hospital, Edinburgh, UK.
  • South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.
  • Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.
  • NIHR CRN North West Coast, Liverpool, UK.
  • University College London Hospitals NHS Foundation Trust, London, UK.

ORCID-Profile: Priyanka Mehta, Jamie Maddox, Jenny O'Nions, Thomas Coats, Rui Zhao, Alex Legg, Anjum B Khan

Zitieren

APA

Mehta, P., Campbell, V., Maddox, J., Floisand, Y., Kalakonda, A. J. M., O'Nions, J., Coats, T., Nagumantry, S., Hodgson, K., Whitmill, R., Amott, I., Flynn, G., Taussig, D., Zhao, R., Cunningham, N., Roset, M., Cuadras, D., Medalla, G., Kuter, H., …, & Khan, A. B. (2024). CREST ‐ UK : Real‐world effectiveness, safety and outpatient delivery of CPX ‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UK. British Journal of Haematology, 205(4), 1326-1336. https://doi.org/10.1111/bjh.19622

Vancouver

Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O'Nions J, et al. CREST ‐ UK : Real‐world effectiveness, safety and outpatient delivery of CPX ‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UK. British Journal of Haematology. 2024;205(4):1326-1336. doi:10.1111/bjh.19622

BibTeX
@article{Mehta2024,
  author = {Mehta, Priyanka and Campbell, Victoria and Maddox, Jamie and Floisand, Yngvar and Kalakonda, Anita J M and O'Nions, Jenny and Coats, Thomas and Nagumantry, Sateesh and Hodgson, Katherine and Whitmill, Richard and Amott, Ian and Flynn, Gillian and Taussig, David and Zhao, Rui and Cunningham, Nicholas and Roset, Montse and Cuadras, Daniel and Medalla, Greg and Kuter, Hayley and Park, Saemi and Legg, Alex and Khan, Anjum B},
  title = {CREST ‐ UK : Real‐world effectiveness, safety and outpatient delivery of CPX ‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UK},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {205},
  number = {4},
  pages = {1326--1336},
  doi = {10.1111/bjh.19622}
}
Kostenlos starten →